Skye Bioscience (SKYE) Net Margin (2013 - 2014)
Skye Bioscience (SKYE) posted quarterly Net Margin of 9.92% for Q2 2014, down 1182.0% year-over-year from 0.92% in Q2 2013, and down 49.18% quarter-over-quarter from 6.65% in Q4 2013.
Skye Bioscience (SKYE) Net Margin (2013 - 2014) Analysis & Trends
Skye Bioscience (SKYE) has reported Net Margin for 2 consecutive years, with 9.92% the latest figure, recorded in Q2 2014.
- In Q2 2014, Net Margin fell 1182.0% year-over-year to 9.92%; the TTM figure through Apr 2014 stood at 32.7% (changed N/A YoY), while the FY2013 annual figure was 1.11%, down 2887.0% from the prior year.
- Net Margin slipped to 9.92% in Q2 2014 per SKYE's latest filing, from 6.65% in the prior quarter.
- Across five years, Net Margin topped out at 1.9% in Q2 2013 and bottomed at 9.92% in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2014 | -9.92% |
| Oct 31, 2013 | -6.65% |
| Jul 31, 2013 | -0.78% |
| Apr 30, 2013 | 1.90% |
| Jan 31, 2013 | 0.28% |